Cascades Capital Asset Management’s AbbVie ABBV Stock Holding History

Cascades Capital Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Buy	5,690 +17	+0.3%	+$3.66K	0.53%	40
2026 Q1	$1.23M	Sell	5,673 -87	-2%	-$19.3K	0.52%	42
2025 Q4	$1.32M	Buy	5,760 +16	+0.3%	+$3.65K	0.55%	37
2025 Q3	$1.33M	Buy	5,744 +17	+0.3%	+$3.46K	0.59%	34
2025 Q2	$1.06M	Buy	5,727 +20	+0.4%	+$3.72K	0.55%	37
2025 Q1	$1.2M	Sell	5,707 -230	-4%	-$44.7K	0.65%	31
2024 Q4	$1.06M	Sell	5,937 -26	-0.4%	-$4.78K	0.56%	34
2024 Q3	$1.18M	Buy	+5,963	New	+$1.11M	0.65%	32

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cascades Capital Asset Management's ABBV Position: Q2 2026 in Review

Cascades Capital Asset Management increased its AbbVie (ABBV) stake by 0.3% in Q2 2026, buying an estimated $3.66K and bringing the position to 5,690 shares worth $1.43M. The position accounts for 0.53% of the portfolio, ranked #40.

Cascades Capital Asset Management first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cascades Capital Asset Management held 5,690 shares of AbbVie worth $1.43M as of Q2 2026.
Cascades Capital Asset Management bought 17 AbbVie shares in Q2 2026, an estimated $3.66K.
AbbVie made up 0.53% of Cascades Capital Asset Management's portfolio in Q2 2026, its #40 holding.
Cascades Capital Asset Management first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cascades Capital Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.